Curcumin sensitizes chemotherapeutic drugs via modulation of PKC, telomerase, NF-κB and HDAC in breast cancer

Therapeutic Delivery

Volumn 2, Issue 10, 2011, Pages 1275-1293

  Roy, Madhumita ^a   Mukherjee, Sutapa ^a   Sarkar, Ruma ^a   Biswas, Jaydip ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; BISINDOLYLMALEIMIDE; CURCUMIN; CYCLOPHOSPHAMIDE; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIVE OIL; PACLITAXEL; PLANT MEDICINAL PRODUCT; PROTEIN KINASE C; TELOMERASE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL LINE; CELL STRAIN MCF 12F; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

EID: 80054096254     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.97     Document Type: Article

References (46)

1. Murthy NS, Chaudhry K, Nadayil D, Agarwal UK, Saxena S. Changing trends in incidence of breast cancer: Indian scenario. Indian J. Cancer 46, 73-74 (2009)
2. Ali S, Olivia A, Li Y, Pettit GR, Sarkar FJ, Philip PA. Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer Chemother. Pharmacol. 52, 235-246 (2003) (Pubitemid 37204538)
3. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell. Biol. 41(1), 40-59 (2009)
4. Mukherjee S, Ghosh U, Bhattacharya NP, Bhattacharya RK, Dey S, Roy M. Curcumin induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Mol. Cell. Biochem. 297, 31-39 (2007) (Pubitemid 46443527)
5. Al-Omar FA, Nagi MN, Abdulgadir MM, Al Joni KS, Al-Majed AA. Immediate and delayed treatments with curcumin prevent forebrain ischemia-induced neuronal damage and oxidative insult in the rat hippocampus. Neurochem. Res. 31, 611-618 (2006) (Pubitemid 43886409)
6. Aggarwal BB. Inflammation and cancer: a silent killer, is not so silent. Current Opin. Pharmacol. 9, 1-4 (2009)
7. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci. 30(2), 85-94 (2008)
8. Mahmmoud YA. Modulation of protein kinase C by curcumin; inhibition and activation switched by calcium ions. Br. J. Pharmacol. 150(2), 200-208 (2007) (Pubitemid 46160610)
9. Bhandarkar SS, Arbisor JL. Curcumin as an inhibitor of angiogenesis. Adv. Exp. Med. Biol. 595, 185-195 (2007)
10. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": From kitchen to clinic. Biochem. Pharmacol. 75, 787-809 (2008)
11. Bianco R, Melisi D, Ciardiello F, Tortora G. Key cancer cell signal transduction pathways as therapeutic targets. Eur. J. Cancer 42, 290-294 (2006) (Pubitemid 43132883)
12. Pan Q, Bao LW, Kleer CG et al. Protein kinase Ce is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res. 65(18), 8366-8371 (2005) (Pubitemid 41330602)
13. Lahn M, Köhler G, Sundell K et al. Protein kinase C a expression in breast cancer. Oncology (Int. J. Cancer Res. Treatment)67(1), 1-10 (2004) (Pubitemid 39370344)
14. Chakraborty S, Ghosh U, Bhattacharya NP, Bhattacharya RK, Roy M. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutat. Res. 596, 81-90 (2006)
15. Zhang J, Tu Y, Schneider SS. Activation of p53, inhibition of telomerase activity and induction of estrogen receptor beta are associated with the anti-growth effects of combination of ovarian hormones and retinoids in immortalized human mammary epithelial cells. Cancer Cell Intl 5, 6 (2005).
16. Indran IR, Hande MP, Pervaiz S. hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function and inhibits ROS-mediated apoptosis in cancer cells. Cancer Res. 71(1), 266-276 (2011)
17. Choi S-H, Im E, Kang H K et al. Inhibitory effects of costunolide on the telomerase activity in human breast carcinoma cells. Cancer Lett. 227, 153-162 (2005) (Pubitemid 41169928)
18. Nishikori M. Classical and alternative NF-kB activation pathways and their roles in lymphoid malignancies. J.Clin.Exp. Hematopathol. 45(1), 15-24 (2005)
19. Cai C, Yao Z. Activation of NF-kB in human breast cancer and its role in cell proliferation and progression. Chin. J. Clin. Oncol. 3(1), 5-10 (2006)
20. Haffner MC, Berlato C, Doppler W. Exploiting our knowledge of NF-kB signaling for the treatment of mammary cancer. J. Mammary Gland Biol. Neoplasia 11, 63-73 (2006) (Pubitemid 44309190)
21. Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kB) signaling in breast cancer. J. Cellular Physiol. 209(3), 645-652 (2006) (Pubitemid 44665682)
22. Ali ZR. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anti Cancer Drugs 21(9), 805-813 (2010)
23. Peserico A, Simone C. Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J. Biomed. Biotechnol. 371832, DOI: 10.1155/2011/371832 (2011)
24. Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur. J. Cell. Biol. 84, 109-121 (2005) (Pubitemid 40353056)
25. Ocker M , Schneider-Stock R. Histone deacetylase inhibitor: signalling towards p21cip1/waf1. Int. J. Biochem. Cell. Biol. 39, 1367-1374 (2007) (Pubitemid 47031035)
26. Margueron R, Duong V, Castet A, Cavaillès V. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem. Pharmacol. 68(6), 1239-1246 (2004) (Pubitemid 39094290)
27. Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 27(5), 244-250 (2006)
28. Martin K. Targeting apoptosis with dietary bioactive agents. Exp. Biol. Med.-231, 117-129 (2006) (Pubitemid 43213448)
29. Mukherjee S, Bhattacharya RK, Roy M. Targeting protein kinase C (PKC) and telomerase by phenethyl isothiocyanate (PEITC) sensitizes PC-3 cells towards chemotherapeutic drug-induced apoptosis. J. Env. Pathol. Toxicol. Oncology 28(4), 269-282 (2009)
30. Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol. 60, 1216-1221 (2007) (Pubitemid 350084541)
31. Kim J, Thorne SH, Sun L, Huang B, Mochly-Rosen D. Sustained inhibition of PKCa reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene 30(3), 323-333 (2011)
32. Li H, Bernard Weinstein I. Protein kinase C b enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res. 66(23), 11399-11408 (2006) (Pubitemid 46009971)
33. Dudek AZ, Zwolak P, Jasinski P et al. Protein kinase C-b inhibitor enzastaurin (LY317615. HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Invest. New Drugs 26(1), 13-24 (2008)
34. Lu D, Sivaprasad U, Huang J, Shankar E, Morrow S, Basu A. Protein kinase C protects MCF-7 cells from TNF-mediated cell death by inhibiting Bax translocation. Apoptosis 12(10), 1893-1900 (2007) (Pubitemid 47498247)
35. Sun R, Gao P, Chen L et al. Protein kinase C {zeta} is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res. 65(4), 1433-1441 (2005) (Pubitemid 40270172)
36. Moon DO, Kim MO, Heo MS, Lee JD, Choi YH, Kim GY. Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells. Archieves Pharmacol. Res. 32(10), 1351-1360 (2009)
37. Ward RJ, Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol. Pharmacol. 68(3), 779-786 (2005) (Pubitemid 41206032)
38. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiateds antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis and inhibition of nuclear factor kB regulated gene products. Cancer Res. 67(8), 3853-3861 (2007) (Pubitemid 46762173)
39. Aggarwal BB. Nuclear factor-kB: the enemy within. Cancer Cell 6, 203-208 (2004)
40. Long L, Cao Y. Down-regulation of Notch1 and NF-kB by curcumin in breast cancer cells MDA-MB-231. Chin. J. Cancer Res. 20(4), 294-300 (2008)
41. Mabuchi S, Ohmichi M, Nishio Y et al. Inhibition of inhibitor of nuclear factor-kB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin. Cancer Res. 10(22), 7645-7654 (2004) (Pubitemid 39557528)
42. Krusche CA, Wuklfing P, Kersting C et al. Histone deacetylase 1 and 3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treatment 90, 15-23 (2005) (Pubitemid 40486997)
43. Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol. Endocrinol. 19(7), 1740-1751 (2005) (Pubitemid 41007887)
44. Fan J, Yin W-J, Lu J-S et al. ER a negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol. 134(8), 883-890 (2008)
45. Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res. 67(11), 5337-5344 (2007) (Pubitemid 46997273)
46. Tabuchi Y, Matsuoka J, Gunduz M et al. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int. J. Oncol. 34, 313-319 (2009).